Acura Pharmaceuticals, Inc. · OTC:ACUR

Acura Pharmaceuticals — Technical Presentation (June 2017)

11 slides from Acura Pharmaceuticals's technical presentation, Jun 28, 2017

  1. Slide 1: Study AP-LTX-401 Topline Results

    June 28, 2017 Study AP - LTX - 401 Topline Results © 2017 Acura Pharmaceuticals, Inc. All Rights Reserved

  2. Slide 2: General Caution Regarding Forward Looking Statements

    2 General Caution Regarding Forward Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forwarding - looking statements involve known and unknown risks, uncertainties an

  3. Slide 3: Study 401 – Design

    3 Study 401 – Design 64 subjects fasted, healthy adults enrolled hydromorphone & LTX - 04P3 34 Subjects 7 Tablets PK Only Hydromorphone & LTX - 04P3 30 Subjects 1 Tablet PK Only Efficacy/Safety (Bioequivalence) Abuse Deterrence (Dose Non - Proportional) Exploratory Protocol 27 Completers 13 Complete

  4. Slide 4: Micro-particle single tablet simulation

    4 LTX - 04 – Micro - particle single tablet simulation Micro - particle MP - 17 was used in Study 400 Micro - particle MP - 25 was used in Study 401 Micro - Particle In Vitro Dissolution in pH2 HCl

  5. Slide 5: Micro-particle multiple tablet simulation

    5 LTX - 04 – Micro - particle multiple tablet simulation Micro - particle MP - 17 was used in Study 400 Micro - particle MP - 25 was used in Study 401 Micro - Particle In Vitro Dissolution in pH7 Water

  6. Slide 6: LTX-04 One Tablet Dose Cmax

    6 LTX - 04 - One Tablet Dose C max Study 400 (n=8) Study 401 (n=27) Given the consistent reduction in Cmax and the differences in the tablets formulations, the single tablets appear to be neutralizing the gastric fluid

  7. Slide 7: Multi-Tablet Dose Cmax

    7 LTX - 04 – Multi - Tablet Dose C max Study 400 (n=8) 8 tablets dose normalized Study 401 (n=13) 7 tablets dose normalized Improved reduction in Cmax reduction in Study 401 may be the result of the MP - 25 micro - particle

  8. Slide 8: One Tablet Dose AUC (0-inf)

    8 LTX - 04 – One Tablet Dose AUC (0 - inf) Study 400 (n=8) Study 401 (n=27)

  9. Slide 9: Study 401 – Conclusions

    9 Study 401 – Conclusions New micro - particle developed with potentially greater abuse deterrent potential and faster release at 1 tablet. New interpretation of the data suggested much more compelling abuse deterrent potential of up to 65% reduction in Cmax . Opportunity to switch to hydrocodone bi

  10. Slide 10: LIMITx™ - Path Forward

    10 • Better understanding of the LIMITx™ Technology • Better understanding of the gastric environment and acidity • Potential for the enhanced abuse deterrent properties for LIMITx • Need to determine the correct level of buffering ingredients to use for a single table through the execution of a dos

  11. Slide 11: Acura Pharmaceuticals, Inc. contact details

    Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 www.AcuraPharm.com www.Nexafed.com www.Oxaydo.com

Acura Pharmaceuticals — Technical Presentation (June 2017) on 6ix